Clinical Trials

25 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07375316 2026-05-26

A ctDNA-guided Phase II Trial of Osimertinib in Combination With Sacituzumab Tirumotecan in EGFR-mutated Advanced NSCLC Patients With Positive ctDNA After lead-in Osimertinib Monotherapy

120 enrolled

Phase 1/2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT05017025 2026-05-20

Aurora Kinase Inhibitor LY3295668 in Combination With Osimertinib for the Treatment of Advanced or Metastatic EGFR-Mutant Non-squamous Non-small Cell Lung Cancer

32 enrolled

Phase 1 Active not recruiting

Lung Neoplasms

NCT04141644 2026-05-19

Osi+Ipi

24 enrolled

Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor (Disorder)

NCT06486142 2026-05-14

ERIS

Phase 3 Recruiting

200 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05401110 2026-05-07

Study of Osimertinib With Carotuximab in Advanced, EGFR-mutated Non-Small Cell Lung Cancer

Phase 1 Recruiting

60 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06014827 2026-05-07

Biologically Guided Radiation Therapy (BgRT) and Stereotactic Body Radiation Therapy (SBRT) to Tyrosine Kinase Inhibitor in Oligoprogressive Oncogenic Positive Non-Small Cell Lung Carcinoma

32 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05624996 2026-05-04

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

Phase 3 Recruiting

474 enrolled

Lung Neoplasms

NCT04591002 2026-04-30

Osimertinib to Suppress the Progression of GGN(EGFR Mutation-positive)

43 enrolled

Phase 1/2 Active not recruiting

Lung Neoplasms

NCT03122717 2026-04-29

Osimertinib and Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer

48 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03586453 2026-04-29

Osimertinib In EGFR Mutant Lung Cancer

30 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06613633 2026-04-29

Third-generation EGFR-TKI Treatment in Metastatic EGFR-mutant NSCLC

Completed

4,000 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02664935 2026-04-28

National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer

Phase 2 Completed

423 enrolled

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms

NCT05528458 2026-04-28

Osimertinib to Suppress the Progression of Remaining GGN for EGFR Mutation-positive Stage IB-IIIA Lung Adenocarcinoma

59 enrolled

GastrointestinalGenitourinaryGynecologic

Adenocarcinoma of Lung

NCT06630325 2026-04-28

A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer

Phase 2 Terminated

6 enrolled 3 charts

Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

NCT03969823 2026-04-24

Whole Genomic Landscape of Advanced EGFR-mutant NSCLC

Phase NA Active not recruiting

148 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07535437 2026-04-21

A Study of Ivonescimab in Combination With Dato-DXd or Osimertinib in People With Non-Small Cell Lung Cancer

Phase 1/2 Recruiting

66 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07323641 2026-04-20

Telisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non Small Cell Lung Cancer

60 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03909334 2026-04-17

Study of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

160 enrolled

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT04479306 2026-04-16

Osimertinib in Combination With Alisertib or Sapanisertib for the Treatment of Osimertinib-Resistant EGFR Mutant Stage IIIB or IV Non-Small Cell Lung Cancer

Phase 1 Completed

37 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06741085 2026-04-13

A Study of Stereotactic Radiosurgery (SRS) and Standard Treatment in People With Lung Cancer That Has Spread to the Brain

56 enrolled

Non Small Cell Lung Cancer Metastatic

NCT03410043 2026-04-06

Osimertinib, Surgery, and Radiation Therapy in Treating Patients With Stage IIIB or IV Non-small Cell Lung Cancer With EGFR Mutations, NORTHSTAR Study

173 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07505173 2026-04-01

HOPE-WBRT

74 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04762199 2026-03-31

MRX-2843 and Osimertinib for the Treatment of Advanced EGFR Mutant Non-small Cell Lung Cancer

Phase 1 Recruiting

69 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03433469 2026-03-30

Osimertinib in Treating Participants With Stage I-IIIA EGFR-mutant Non-small Cell Lung Cancer Before Surgery

27 enrolled 14 charts

Carcinoma, Non-Small-Cell Lung

NCT06538038 2026-03-27

Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients

Recruiting

538 enrolled

Phase 1/2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07491211 2026-03-27

Osimertinib Combined With Intracranial SRT for EGFR-Mutant NSCLC With Symptomatic Brain Metastases

Active not recruiting

300 enrolled

CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT07486648 2026-03-24

Precision

53 enrolled

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07485452 2026-03-20

OSIBBBOOST

7 enrolled

Phase 1/2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT04285671 2026-03-10

Necitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung Cancer

30 enrolled

Phase 1 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05166616 2026-03-05

Minnelide and Osimertinib for the Treatment of Advanced EGFR Mutated Non-Small Cell Lung Cancer

8 enrolled